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Background: Chronic low-grade inflammation and alterations in innate and adaptive
immunity were reported in Type 2 diabetes (T2D). Here, we investigated the abundance
and activation of T cells in the bone marrow (BM) of patients with T2D. We then verified
the human data in a murine model and tested if the activation of T cells can be rescued
by treating mice with abatacept, an immunomodulatory drug employed for the treatment
of rheumatoid arthritis. Clinical evidence indicated abatacept can slow the decline in
beta-cell function.
Methods: A cohort of 24 patients (12 with T2D) undergoing hip replacement surgery
was enrolled in the study. Flow cytometry and cytokine analyses were performed on BM
leftovers from surgery. We next compared the immune profile of db/db and control wt/db
mice. In an additional study, db/db mice were randomized to receive abatacept or vehicle
for 4 weeks, with endpoints being immune cell profile, indices of insulin sensitivity, and
heart performance.
Results: Patients with T2D showed increased frequencies of BM CD4+ (2.8-fold,
p = 0.001) and CD8+ T cells (1.8-fold, p = 0.01), with the upregulation of
the activation marker CD69 and the homing receptor CCR7 in CD4+ (1.64-fold,
p = 0.003 and 2.27-fold, p = 0.01, respectively) and CD8+ fractions (1.79-fold,
p = 0.05 and 1.69-fold, p = 0.02, respectively). These differences were confirmed
in a multivariable regression model. CCL19 (CCR7 receptor ligand) and CXCL10/11
(CXCR3 receptor ligands), implicated in T-cell migration and activation, were the
most differentially modulated chemokines. Studies in mice confirmed the activation of
adaptive immunity in T2D. Abatacept reduced the activation of T cells and the levels
of proinflammatory cytokines and improved cardiac function but not insulin sensitivity.
Santopaolo et al. Adaptive Immunity in Type 2 Diabetes
Conclusions: Results provide proof-of-concept evidence for the activation of BM
adaptive immunity in T2D. In mice, treatment with abatacept dampens the activation
of adaptive immunity and protects from cardiac damage.
Keywords: diabetes, immunity, bone marrow, cardiovaacular, adipo/cytokines
RESEARCH IN CONTEXT
What Is Already known?
• Type 2 diabetes (T2D) is characterized by systemic low-grade
inflammation and activation of innate and adaptive immunity,
which supports the novel medical theory that T2D is an
autoimmune disease. The bone marrow (BM) is a primary
immune organ. People with T2D have a fatty BM characterized
by inflamed adipocytes that accumulate at the expense of
hematopoietic cells and vascular cells.
• Abatacept, an immunomodulatory drug that acts through the
selective inhibition of T-cell co-stimulation, was approved for
rheumatoid arthritis in 2007. The drug has shown favorable
action in preserving beta cell function in patients with
rheumatoid arthritis, possibly due to its anti-inflammatory and
immunomodulatory properties.
What Is the Key Question?
• Is adaptive immunity activated in the BM of patients
with T2D?
• Do mice with T2D model the condition seen in patients?
• If so, can abatacept treatment rescue T-cell activation, thereby
benefiting metabolic control and cardiac function?
What Are the New Findings?
• Patients and mice with T2D show a shift in the prevalent
subsets of BM T lymphocytes, with enrichment of
activated cells.
• Treatment of obese, T2D mice with abatacept rescued
the altered adaptive immune profile and improved heart
performance, without improving insulin sensitivity.
How Might This Impact Clinical Practice in
the Foreseeable Future?
• The BM requires clinical attention as a target and
trigger of inflammatory responses involving cells of the
adaptive immunity.
• Multicenter trials are warranted to extend the implication
of the study to the general population affected by T2D, to
determine if those with an activation of adaptive immunity
develop more cardiovascular complications.
Abbreviations: APCs, antigen-presenting cells; BM, bone marrow; BMMCs, BM
mononuclear cells; CO, cardiac output; TCM, central memory T cells; CCR7, CC-
chemokine receptor 7; DCs, dendritic cells; EDV, end diastolic volume; TEM,
effector memory T cells; ND, non-diabetic; HSPCs, hematopoietic stem/progenitor
cells; SV, stroke volume; TEMRA, terminally differentiated T memory cells; T2D,
type 2 diabetes; VAT, visceral adipose tissue; PBS, phosphate buffered saline; RT,
room temperature; EDTA, ethylenediaminetetraacetic acid; RT, room temperature;
FACS, flow cytometry staining; RPMI, Roswell Park Memorial Institute; RBS, red
blood cell; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
• Modern immunomodulatory drugs that disable just the initial
stage of lymphocyte activation leaving the remaining immune
army unscathed may represent a novel approach to prevent
cardiovascular complications.
BACKGROUND
Chronic low-grade inflammation plays an important role in the
progression of type 2 diabetes (T2D)mellitus and in the increased
propensity of diabetic people to develop cardiovascular disease,
infections, and cancer (1–4). Both innate and adaptive immunity
play key roles in the development of metabolic inflammation
and insulin resistance (5–11). Cross-sectional results from the
Multi-Ethnic Study of Atherosclerosis (MESA) highlighted the
association of T2D with adaptive immune response, reflected
by higher memory and lower naive CD4+ cells (12). Moreover,
higher levels of CD4+ memory cells have been reported in the
peripheral blood of T2D subjects with cardiovascular disease as
compared with those without, suggesting a state of exacerbated
immune activation may be implicated in the development of
complications (13). Likewise, T lymphocytes infiltrate the visceral
adipose tissue (VAT), where they play pivotal roles in the
regulation of mechanisms at the intersection of metabolism and
immune tolerance (14–17). However, scanty information exists
on the T-cell activation in the bone marrow (BM), a tissue crucial
for the production and maturation of immune cells.
The BM not only functions as a primary B lymphocyte-
producing organ but also represents a site where immune cells are
formed, mature, and/or recirculate. Furthermore, the BM plays a
key role as a secondary lymphoid organ, crucial for CD4 and CD8
cell-related responses, as well as a site of preferential homing and
persistence for memory T cells (18, 19). These comprise subsets
with important and specific functionalities, such as T cells, B cells,
dendritic cells (DCs), and macrophages. In the BM, memory T
cells that maintain a state of readiness after tissue injury can
rapidly expand andmount a robust secondary cytotoxic response
in case of new challenges, more potently than that afforded by
other lymphoid and non-lymphoid organs (20, 21). T cells can
home into the BM from the circulation and persist within this
organ contributing to systemic immune memory (22). Moreover,
the BM contains central CD4 Foxp3 Tregs, which not only
suppress the effector T cells but also exert non-immune actions,
such as vascular protection, metabolic homeostasis, and tissue
repair (23, 24). Immune regulation occurs in the BM through
direct cell–cell contacts and soluble factors, including cytokines
and chemokines.
Several studies have shown that people with T2D incur a
remarkable remodeling of BM, consisting of an accumulation
of inflamed adipocytes and depletion of hematopoietic,
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neuronal, and vascular cells (25–28). These changes impinge on
hematopoietic cell functions and contribute to altering the profile
and mobilization capacity of hematopoietic stem/progenitor
cells (HSPCs) (29, 30). An altered phenotype of released HSPCs
reportedly conveys antiangiogenic and proapoptotic features
to the peripheral vasculature, thereby contributing to diabetic
complications (31). Based on this background, we posit that T2D
could also impact BM immune cell homeostasis.
Modern immunomodulatory drugs, which—at variance from
classical immunosuppressive agents—disable just a particular
type of lymphocyte or interfere with the initial state of
lymphocyte activation, leaving the global immune response
intact, are attracting much clinical attention. One of these
compounds, abatacept, exerts anti-inflammatory activity via
the selective modulation of T-cell co-stimulation. In Europe,
abatacept is approved for use in patients with highly active
and progressive rheumatoid arthritis (32). Interestingly, clinical
studies in patients with rheumatoid arthritis have shown that
abatacept treatment reduced the risk of diabetes and improved
markers of metabolic control, through an anti-inflammatory
mechanism preserving β-cell function (33–35). However, it
remains unknown if abatacept can impact adaptive immune
response and preserve target organ damage in diabetes.
The present study was a proof-of-concept investigation
assessing the frequencies and activation state of immune cell
subsets in the BM of patients with T2D compared with non-
diabetic (ND) individuals, with a focus on activated and memory
T cells. After confirming human results in a murine model
of T2D, we performed a therapeutic preclinical study in a
murine model of T2D to determine the effect of abatacept on
adaptive immunity, cytokine secretion, metabolic control, and
cardiac function.
RESEARCH DESIGN AND METHODS
Human Studies
Patients undergoing hip replacement surgery were recruited
under informed consent at the Avon Orthopedic Centre,
Southmead Hospital, Bristol, UK. The study protocol complied
with the Declaration of Helsinki was covered by institutional
ethical approval (REC14/SW/1083 and REC14/WA/1005) and
was registered as an observational clinical study in the
National Institute for Health Research Clinical Research Network
Portfolio, UK Clinical Trials Gateway. Demographic and clinical
data of the 24 enrolled subjects are reported in Table 1.
Type 2 diabetes was diagnosed according to the American
Diabetes Association guidelines. Specifically, it was defined as (1)
patient/referring doctor reports a previous diagnosis of diabetes,
and (2) HbA1c > 48 mmol/mol. We excluded subjects with
acute disease/infection, inflammatory/immune diseases, current
or past hematological disorders or malignancy, unstable angina,
recent (within 6 months) myocardial infarction or stroke, heart
failure, liver failure, dialysis, and pregnancy.
Human Bone Marrow Collection and Processing
Bone marrow samples were obtained from scooped femur heads
remaining from hip replacement surgery. Only material that
TABLE 1 | Characteristics of study subjects.
ND (n = 12) T2D (n = 12) P =
Age, years 64.0 ± 3.5 70.8 ± 3.0 N.S.
Male, % 50 66 N.S.
BMI, kg/m2 26.6 ± 1.6 33.4 ± 1.9 0.018
HbA1c, mmol/mol N.D. 53.3 ± 2.7
Smoking, % 42 50 N.S.
Hypertension, % 66 75 N.S.
Coronary Artery Disease, % 17 66 0.01
Medications
Insulin, % 0 42 0.01
Oral anti-diabetic drugs, % 0 66 0.01
Statins, % 25 83 0.01
Anti-hypertensive drugs, % 42 50 N.S.
would otherwise be discarded was collected for the study. During
the replacement procedure, the femoral head was removed with
a saw, and the proximal femoral canal was opened with reamers
and rasps. The BM displaced into the wound was scooped
into a sterile pot with a curette. The sample was decanted
into a collection tube with 0.5 mol/L ethylenediaminetetraacetic
acid (EDTA), pH 8 (Thermo Fisher Scientific, Gloucester, UK,
#28348) labeled, and placed in a fridge for collection by the
investigator within 1 h.
The diluted BM suspension was passed through a 100-µm
filter to remove bone fragments and cell clumps. The sample was
stratified on Ficoll Histopaque 1077 (Sigma-Aldrich, St. Louis,
MO, USA, #10771) and centrifuged without acceleration or brake
at 300 × g for 45min at 24◦C. Mononuclear cells sedimented at
the interphase were then collected, washed twice with phosphate
buffered saline (PBS), assessed for viability by trypan blue
staining (Thermo Fisher Scientific, #15250061), and counted at
microscopy. Plasma was separated from freshly collected human
BMmononuclear cells (BMMCs) through centrifugation at 3,500
rpm for 10min and frozen immediately at−80◦C.
Flow Cytometry Analysis of Human Bone Marrow
Samples
The following monoclonal antibody combinations were
used to characterize the phenotype of different immune cell
subsets: anti-CD45RO-BB515 (#564529), anti-CD3-PE-cy5.5
(#340949), anti-CD4-PE-cy5.5 (#35-0047-42), anti-CD8-PE-cy5
(#15-0088-42), anti-CD45RA-BV605 (#562886), anti-CD25-PE-
cy7 (#557741), anti-CD69-APC (#310910), anti-CCR7-Aleza700
(#565867), anti-CD45 BV771 (#304050), anti-CD56PE-cy7
(#557747), anti-CD8-BV510 (#563256), anti-CD19-APC
(#340722), anti-CD4BV421 (#565997), anti-CD3PE #340662),
and anti-CD19BV785 (#363028). All antibodies were titrated for
optimal staining performance.
Cell viability was determined using Zombie NIRTM Fixable
Viability Kit (BioLegend, San Diego, CA, USA; #423106). Briefly,
70 × 106 BMMCs (at a concentration of 1 × 106 cells/ml)
were stained with Zombie NIRTM Fixable Viability Kit for 30min
at room temperature (RT). Then, the cells were washed with
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Flow Cytometry Staining Buffer (FACS buffer) (eBioscienceTM
Flow Cytometry Staining Buffer, eBioscience, Inc., San Diego,
CA, USA; #00-4222-57) at 300 × g for 10min. The staining
protocol included the use of an Fc blocking antibody (True-
StainMonocyte Blocker, BioLegend, #426102) to control for non-
specific binding and background fluorescence. Each sample was
added with 100 µl Fc blocking antibody (diluted in FACS buffer
at 1:50 ratio) and incubated on ice for 20min. The cells were
then centrifuged at 500 × g for 5min at 4◦C. Subsequently,
BMMCs were stained with a defined combination of antibodies,
at the appropriate dilutions, in FACS buffer for 20min at 4◦C.
Cells were washed twice in FACS buffer and stained with 1%
PFA. A minimum of 2 × 106 cells/ml was assayed in the flow
cytometry studies. Fluorescence minus one (FMO) controls were
included in buildingmulticolor flow cytometry panels. Moreover,
BD Comp Beads (#560497) were used to optimize fluorescence
compensation settings in multicolor flow cytometry studies. The
analysis was performed on a BD LSR II Fortessa X20 (Becton
Dickinson, San Jose, CA, USA) using FlowJo software (TreeStar,
San Carlos, CA, USA).
Animal Studies
Experiments were performed following the Guide for the
Care and Use of Laboratory Animals (The Institute of
Laboratory Animal Resources, 1996) and with the approval
of the University of Bristol and the British Home Office
(license 30/3373). As a model of T2D, we used a 10-week-
old male obese leptin receptor homozygous mutant BKS.Cg-
+Leprdb/+Leprdb/OlaHsd (db/db) mice (Envigo, Blackthorn,
UK). Age- and sex-matched lean heterozygous + BKS.Cg-
+Leprdb/+LeprWT/OlaHsd (db/WT) mice served as controls.
Animals were maintained in the high standard animal facilities
of the University of Bristol, under the surveillance of specialists
trained in husbandry and welfare of the species. The animals
fed standard chow (EURodent Diet 22%, www.LabDiet.com)
and provided water ad libitum. Glucose was measured in urine
using Diastix colorimetric reagent strips (Bayer, Reading, UK).
At sacrifice, the BM, spleen, and peripheral blood were collected
according to the procedures described below.
Abatacept Treatment
Abatacept (250mg lyophilized powder per vial, Bristol-Myers
Squibb, Princeton, NJ, USA) was purchased from the Bristol
University Hospital Pharmacy. The drug was reconstituted at 2×
of the concentration required in sterile distilled water (25mg/ml).
The vial was gently swirled until the complete dissolution of the
compound. The reconstituted material was diluted with sterile
pH-checked PBS for in vivo use on the same day of preparation.
A cohort of twelve 10-week-old male db/db mice was
randomized for treatment with abatacept or vehicle. Mice were
injected intraperitoneally with 300 µg abatacept in 100 µl
PBS, three non-consecutive times a week, for 4 weeks, while
controls received the vehicle. The dosage and control choice were
adapted from a previous abatacept study in a murine model of
cardiomyopathy (36). Dimensional and functional parameters
of the heart were measured before sacrifice using a Vevo3100
echocardiography system, using an MX400 transducer (Fujifilm
VisualSonics Inc, Toronto, ON, Canada). The echocardiography
study was performed withmice under isoflurane anesthesia (2.5%
for induction, followed by 0.5–1.2% as appropriate to maintain
the heart rate between 400 and 450 bpm).
Collection and Processing of Bone Marrow
At sacrifice, whole BM cells were obtained from the mouse
tibiae and femora. Both ends of the bones were cut using sterile,
sharpened scissors. BM cells were harvested by repeated flushing
of the bone shaft in 1ml PBS in a tube using a syringe provided
with a 23-gauge needle. After removal of aggregates from the BM
suspension by vigorous pipetting and filtration through a 70-µm
mesh nylon strainer (#07-201-431, Thermo Fisher Scientific), the
sample was centrifuged at 300 × g for 10min. The pellets were
resuspended to obtain a suspension of 2 × 106 cells/ml in fresh
PBS for use in cytometry analysis. Supernatants were collected for
cytokine assays and stored at−20◦C.
Collection and Processing of Splenocytes
Mononuclear spleen suspensions were prepared by gently
pressing the spleen tissue with the flat end of a syringe in 5ml of
Roswell Park Memorial Institute Medium (RPMI) containing 1%
pen/strep, on a 100-mm culture dish. Then, the cell suspension
was passed through on a 70-µm cell strainer into a 50-ml tube.
After washing twice with 5-ml RPMI, the cell suspension was
centrifuged at 300 × g for 10min, and cells were resuspended
in eBioscienceTM 1× red blood cell (RBC) Lysis Buffer (#00-
4333-57) on ice for 3min. Finally, splenocytes were washed,
resuspended in PBS at a concentration of 2 × 106 cells/ml,
and counted.
Collection and Processing of Peripheral Blood
At sacrifice, the blood was harvested with an EDTA-coated
syringe from the left ventricle and placed into Eppendorf tubes
(Eppendorf, Hamburg, Germany). Blood was centrifuged for
15min at 3,000 rpm (1,500 × g) at 4◦C. After centrifugation,
the plasma was removed, and the pellet was incubated with 1×
RBC Lysis Buffer on ice for 10min. Mononuclear cells were then
resuspended at 2 × 106 cells/ml in PBS. Plasma was stored at
−80◦C for later analysis.
Flow Cytometry Analyses
Immunofluorescence surface staining was performed by adding
a panel of directly conjugated mAb to freshly prepared BMMCs,
splenocytes, and peripheral blood mononuclear cells. Before
staining, cell viability was assessed using Zombie NIRTM Fixable
Viability Kit (#423106) for 30min at RT. For all experiments,
cell suspensions were preincubated with anti-CD16/CD32 mAb
(BioLegend) to block FcγRII/III receptors. Cell staining was
performed in the dark for 20min at 4◦C in FACS staining buffer
(BD, #554656). The following reagents were used: CD4-PE-cy5.5
(#35-0042-82), CD8-PE-cy5 (#15-0083-81), CD25-FiTC (#130-
120-172), CD45-BV785 (#103149), CD69 PE-Vio R©770 (#30-
103-944), NK1.1-AF700 (#108729), CD19-BV510 (#115545),
CD44-Super Bright (#63-0441-82), CD62l BV650 (#564108),
F4/80-APC (#123115), CD206-PE (#141705), CD11b-PE-cy 7
(#101215), CD80-PEdazzle (#104737), CD11c-BV605 (#117333),
and MHCII-AF700 (#107621). The proliferation of CD4+
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and CD8+ cells was assessed using the KI67-BV510 marker
(#563462). Cells were fixed and permeabilized using the BD
PharmingenTM Transcription Factor Buffer Set Kit (#562574;
BD Pharmingen Inc., San Diego, CA, USA). A minimum of
2 × 106 cells/ml was assayed in the flow cytometry studies.
BD Anti-Mouse Ig, κ/Negative Control (BSA) Compensation
Plus (7.5µm) Particles Set (#560497) were used to optimize
fluorescence compensation settings in multicolor flow cytometry
analysis. Cells were analyzed on LSR II Fortessa X20 Flow
Cytometry instrument using the FlowJo software.
Cytokine Profiling
Cytokine content in plasma separated from BM was measured
using the Proteome Profiler Human Cytokine Array Kit
(Research & Diagnostic Systems, Inc, Minneapolis, MN, USA;
#ARY005B). A dedicated mouse Cytokine Array Kit (#ARY006)
was used to measure cytokines in the BM supernatants and
the plasma isolated from the peripheral blood. The cytokines
were detected by exposing the membrane to X-ray film, which
was subsequently developed with ChemiDoc XRS+ System by
Bio-Rad (Hercules, California, USA). The mean luminescence
was normalized to reference spots from the same membrane
following background correction. Pixel densities on developed X-
ray filmwere analyzed using Fiji—ImageJ image analysis software
(National Institutes of Health, Bethesda, MD, USA).
Insulin and Glucose Assays
Plasma levels of insulin and glucose were measured using
colorimetric assay kits (from Thermo Fisher Scientific, #EMINS,
and Abcam, #ab65333, respectively). The quantitative insulin
sensitivity check index (QUICKI) was calculated according to
the formula QUICKI = 1/(logI0 + logG0), where I is insulin
(µU/ml) and G is glucose (nmol/µl). In addition, the HOMA-
IR formula was calculated as fasting insulin multiplied by fasting
glucose divided by 22.5.
Statistical Analysis
Values are presented as mean ± SEM. Two-tailed independent-
samples t-test was used to compare groups with T2D and without
diabetes. Value of p< 0.05 was considered statistically significant.
RESULTS
T2D Increases the Frequency of T
Lymphocytes in Human BM
The two studied groups were similar regarding age and sex
distribution (Table 1). The average body mass index (BMI) was
26.6 ± 1.6 in ND subjects and 33.4 ± 1.9 in patients with
T2D, thus classifying them as overweight and obese, respectively.
Coronary artery disease was 3.9-fold more frequent in patients
with T2D. In addition, the assessment of HbA1c levels (53.3
± 2.7 mmol/mol) indicated that the patients with T2D had
an acceptable metabolic control with insulin (42%) and/or oral
anti-diabetic drugs (66%).
The flow cytometry analysis of BM cells was performed on
data of the CD45/SSC gating, where lymphocytes showed the
highest CD45 fluorescence intensity and the lowest SSC signal
(Figures 1A–C). As indicated in section Research Design and
Methods, the FMO control was used as a control in all the
experiments. Cell viability was consistently >90% (Figure 1B).
There were no differences in the total cellularity per ml of sample
(data not shown) and the frequency of CD45 cells between
T2D and ND groups (Figure 1C, p = 0.88). We next analyzed
lymphocytes, namely, T cells (CD45+CD3+), natural killer (NK)
cells (CD45+CD16+CD56+), and B cells (CD45+CD19+) using
the gating strategy shown in Figure 1D. This characterization
demonstrated an increase in the frequency of T cells (2.47-
fold, p < 0.001) and NK cells (2.36-fold, p = 0.005) in T2D
compared withND, whereas B cells did not differ between the two
groups (p = 0.17) (Figures 1E–G). T lymphocytes were further
subdivided into CD4+ and CD8+ cells. Results indicated an
increased frequency of both CD4+ (2.77-fold, p = 0.001) and
CD8+ T cells (1.84-fold, p = 0.01) in T2D compared with ND
(Figures 1H–J). Values are mean, with single points indicating
individual samples.
T2D Increases the Frequency of Activated
T Lymphocytes
T cells are activated through the presentation of antigens
expressed on the surface of antigen-presenting cells (APCs).
Once activated, they divide rapidly and secrete cytokines that
regulate and sustain the immune response. Previous studies have
shown that the human BM contains T cells in the activated state
as denoted by the expression of CD69 (37). Here, we report that
BM CD4+ and CD8+ T cells from patients with T2D have a
heightened activation state compared with ND individuals, as
indicated by an increased frequency of CD69 (Figure 2A). The
highest expression of CD69 was observed in the CD4+ fraction,
which was increased 3.64-fold in T2D (p = 0.003 vs. ND), while
the increase was 1.79-fold for the CD8+ fraction (p = 0.05
vs. ND) (Figures 2B,C). We looked for confirmation of T-cell
activation by checking the expression of the late marker CD25.
Data indicate a more modest difference between the two groups,
not reaching statistical significance (p= 0.15 and 0.07, for CD4+
and CD8+ cells, respectively) (Figures 2D,E).
Type 2 Diabetes Increases the Frequency
of CCR7-Expressing T Lymphocytes
The CC-chemokine receptor 7 (CCR7) and its ligands play a
key role in lymphocyte homing to lymphoid tissue. In the T2D
group, both CD4+ and CD8+ lymphocytes expressed CCR7
with higher frequency than the ND group (2.27-fold, p =
0.01; and 1.69-fold, p = 0.02, respectively) (gating is shown in
Figure 2A and results in Figures 2F,G). Moreover, we combined
CCR7 and CD45RA antigens in the flow cytometry analysis to
distinguish naïve and memory subpopulations (gating strategy
is shown in Figure 3A). Naive CCR7+CD45RA+ T cells were
more abundant in T2D, with 19.9 ± 5.4% of the CD4+ cell
subfraction expressing this phenotype (2.46-fold more than ND,
p = 0.04) (Figure 3B). Within CD8+ cells, naive T lymphocytes
averaged 16.2 ± 3.2% (1.76-fold more than ND, p = 0.09)
(Figure 3C). Naive lymphocytes are patrolling precursor cells
that travel in and out of lymphoid organs in search of cognate
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FIGURE 1 | Flow cytometry analysis of immune cells in human bone marrow shows type 2 diabetes (T2D) is associated with an increased abundance of CD4+ and
CD8+ cells. Scooped bone marrow (BM) from femoral head leftovers of orthopedic surgery was obtained from patients previously diagnosed to have T2D and
controls without T2D (ND). (A) Lymphocytes were gated based on SSC-A vs. FSC-A, and singlets were selected from the FSC-A vs. FSC-H dot plot. (B)
Subsequently, dead cells were excluded with Zombie NIRTM Fixable Viability Kit. (C–G) Lymphocytes were gated based on SSC-A vs. FSC-A, and singlets were
selected from CD45+ cells to identify population subsets according to the staining for CD3 (T lymphocytes), CD19 (B lymphocytes), and CD16/CD56 (NK cells). (H–J)
Gating for CD4 and CD8 (H) Bar graphs showing the frequency of CD4+ cells (I) CD8+ cells (J). Reported frequencies are illustrative of a representative case for each
group. Values are mean ± SEM, with each point representing an individual case.
antigens. Hence, changes in the local microenvironment might
have contributed to the recruitment and homing of naive
cells to the BM. Here, APCs could induce the differentiation
into immune cells capable of effector responses. To test this
possibility, we next investigated the influence of T2D on central
memory (TCM, CCR7+ CD45RA−), effector memory (TEM,
CCR7− CD45RA), and “revertant” terminally differentiated T
memory cells (TEMRA, CCR7− CD45RA+). TCM and TEM
cells were similar between groups (Figures 3D–G), whereas T2D
was characterized by a reduction in the frequency of CD4+ and
CD8+ TEMRA (0.34-fold, p = 0.006; and 0.47-fold vs. ND, p =
0.009, respectively) (Figures 3H,I).
A multivariable regression model including age, sex, and
BMI as covariates confirmed the differences emerging from the
univariate analysis illustrated in previous paragraphs.
Altered Chemokine Profile in the BM of
Patients With T2D
We next examined the expression of a panel of cytokines,
chemokines, and proteins in BM perfusates from three patients
with T2D and three ND subjects. Of 104 measured factors, 65
were upregulated and 2 downregulated in T2D BM, considering
a threshold fold change ≥2 (Figure 4A, Table 2).
An analysis conducted using the STRING database revealed
that most of the differentially regulated factors were connected in
a network with a PPI enrichment p-value: <1.0e−16 (Figure 4B).
The highly significant interaction highlights the biological
relevance of the phenomenon. Interestingly, in the cytokine
series, IL-18, and IL-31 were the most upregulated (both over
13-fold). Among chemokines, CXCL10 and CXCL11 (CXCR3
receptor ligands), MCP-1 (CCR2 ligand), and CCL19 (CCR7
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FIGURE 2 | Increased relative abundance of activated T cells in the bone marrow (BM) of patients with T2D. (A) Representative histogram overlays of CD4+ (left
panels) and CD8+ cells (right panels) expressing the activation markers CD25 (late marker), CD69 (early marker), and chemokine receptor CCR7 (black line histogram)
and FMO control (gray dotted histogram). BM-MCs were stained as described in Materials and Methods with mAb mixture containing BV771-CD45, PE-cy5-CD8,
PE-cy5.5-CD4, PE-cy7-CD25, APC-CD69, and Alexa700-CCR7. Reported frequencies are illustrative of a representative case for each group. (B,C) Relative
frequency of CD69 within CD4+ and CD8+ cells. (D,E) Relative frequency of CD25 within CD4+ and CD8+ cells. (F,G) Relative frequency of CCR7 within CD4+ and
CD8+ cells. Values are mean ± SEM, with each point representing an individual case.
receptor ligand), which are implicated in T-cell migration to
sites of inflammation, emerged as the most upregulated factors
(all over 3.5-fold). Another ligand for CCR7, CCL21, was
not measured because not included in the array, with this
representing a limitation of the study. Twenty-six proteins
were modulated, including VEGF-A, Complement C5, and EGF
(all showing an increase >14-fold). Moreover, basigin (alias
CD147), which functions as a receptor for soluble cyclophilins
and is involved in cyclophilin-mediated viral infection (38),
was upregulated in T2D, together with its transcriptional target
MMP-9; whereas LIF, an inhibitor of immune response afforded
by T lymphocytes (39), and CD40L, a costimulatory ligand
for CD40 involved in modulation of lymphocyte activation
(40), were downregulated. Analysis of covariance detected a
strong overall effect of T2D on the analyzed factors (p <
0.001). Multiple comparison analysis documented a significant
difference regarding VEGF-A (p = 0.03), basigin (p = 0.01),
chitinase-3-like protein 1 (p = 0.003), and insulin-like growth
factor-binding protein 2 (p= 0.008).
Analysis of Murine BM Confirms the
Impact of T2D on the Frequency and
Activation of T Lymphocytes
We next sought confirmation about the influence of T2D
on immune cells by assessing the phenotype of different
cell populations in the BM, spleen, and peripheral blood
from 10-week-old db/db and control age-matched wt/db mice
(Figure 5A). Confirmation of the diabetic state in the db/db
group was achieved by the verification of persistent overt
glycosuria. Flow cytometry analysis demonstrated db/db mice
had substantial increases in the frequency of CD4+ and CD8+
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FIGURE 3 | Increased relative abundance of CCR7 expressing T lymphocytes in BM of patients with T2D. (A) Gating strategy for identification of CCR7 and CD45RA.
The numbers indicate the percentage of naïve T cells (CCR7+ CD45RA+, top right quadrant), central memory T cells (TCM, CCR7+ CD45RA−, top left quadrant),
effector memory T cells (TEM, CCR7− CD45RA−, bottom left quadrant), and terminal effector T cells (TEMRA, CCR7− CD45RA+, bottom right quadrant) gated on the
forward and side scatter of the lymphocyte populations. Reported frequencies are illustrative of a representative case for each group. (B–I) Bar graphs showing the
relative frequency of CCR7+ CD45RA+ naive cells in CD4+ (B) CD8+ cells (C) CCR7+ CD45RA− TCM cells in CD4+ (D) and CD8+ cells (E), CCR7− CD45RA− TEM
cells in CD4+ (F) and CD8+ cells (G) CCR7−CD45RA+ TEMRA cells in CD4+ (H) and CD8+ cells (I). Values are mean ± SEM, with each point representing an
individual case.
cells in the BM (1.88-fold, p = 0.02; and 2.23-fold, p= 0.005,
respectively), spleen (1.53-fold, p < 0.0001; 1.27-fold, p = 0.04,
respectively), and peripheral blood (1.66-fold, p= 0.007; and
1.71-fold, p = 0.004) (Figures 5B,C), which were associated
with decreased abundance of CD19+ B cells in the BM
(0.67-fold, p < 0.0001), but not in the spleen or peripheral blood
(Figure 5D). Regarding NK cells, higher numbers were found in
BM of db/db mice (1.77-fold, p = 0.01), whereas no difference
was observed in the other two districts (Figure 5E).
We also extended the analysis beyond lymphocytes to
macrophages, identified as CD11b+F4/80+ cells; they were more
abundant in db/db mice at the level of BM (9.25 ± 0.89 vs.
5.77 ± 0.58% in wt/db, p = 0.04) and peripheral blood (15.25
± 3.02 vs. 8.17 ± 1.64% in wt/db, p = 0.003), but not in the
spleen (4.25± 0.76 vs. 2.02± 0.40% in wt/db, p= 0.56). The M1
subtype, represented by CD80+, showed a tendency to increase
in the examined sites, albeit not statistically significant (BM:
8.15 ± 1.25 vs. 4.96 ± 1.12% in wt/db, p = 0.07; spleen: 3.91
± 0.46 vs. 2.53 ± 0.46% in wt/db, p = 0.07; peripheral blood
7.68 ± 2.07 vs. 3.96 ± 1.16% in wt/db, p = 0.18). No difference
was observed between groups for CD206+ M2 macrophages or
MHCII+CD11c+CD11b−CD123− DC (data not shown).
Next, we assessed the specific subsets of CD4+ and CD8+
cells using immunostaining for the marker of activation CD25.
No difference between db/db and wt/db mice was observed
regarding CD4+ cells (data not shown). In contrast, as shown in
Figure 5F, higher levels of CD8+ cells stained positive for CD25
in db/db mice at the level of the BM (3.87-fold, p= 0.02) but
not in the spleen or peripheral blood. Finally, we determined the
expression of CD103, an integrin that identifies tissue-resident-
memory CD8+ cells with an immunosurveillance and protective
function (41) and is dynamically involved in the functional
differentiation of some cytotoxic T cells (42). As shown in
Figure 5G, CD8+CD103+ cells were higher in db/db mice at the
level of all examined tissue (p < 0.01).
Diabetic Mice Show a Redistribution of
Naive and Central Memory T Cells From
Peripheral Blood (PB) to the BM
CD4+ and CD8+ cells were further categorized into naïve
and memory phenotypes based on the expression CD44 and
CD62L, with the CD44−CD62Lhigh population being considered
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FIGURE 4 | Altered chemokine profile in BM of patients with T2D. (A) Spider graph showing the expression levels of chemokines, cytokines, and proteins measured
using a proteome profiling array in bone marrow perfusates of three subjects per group. Pink line (T2D) and the blue line (ND). (B) The network of factors found to be
differentially regulated between T2D and ND. The bar halo color is based on the rank of the protein in the set of input values. Action types are shown as:
.
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TABLE 2 | List of modulated factors in human bone marrow with value of the fold change vs. ND.
Node Annotation Fold change p-value
CD40LG CD40 ligand; Cytokine that binds to CD40/TNFRSF5. Costimulates T-cell proliferation and
cytokine production. Its cross-linking on T-cells generates a costimulatory signal which
enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and
CD28 costimulation. Induces the activation of NF-kappa-B and kinases MAPK8 and PAK2
in T- cells. Induces tyrosine phosphorylation of isoform 3 of CD28. Mediates B-cell
proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4.
Involved in immunoglobulin class switching (By similarity)
0.48 0.41
LIF Leukemia inhibitory factor; LIF has the capacity to induce terminal differentiation in
leukemic cells. Its activities include the induction of hematopoietic differentiation in normal
and myeloid leukemia cells, the induction of neuronal cell differentiation, and the
stimulation of acute-phase protein synthesis in hepatocytes; Endogenous ligands
0.48 0.85
BDNF Brain-derived neurotrophic factor; During development, promotes the survival and
differentiation of selected neuronal populations of the peripheral and central nervous
systems. Participates in axonal growth, pathfinding and in the modulation of dendritic
growth and morphology. Major regulator of synaptic transmission and plasticity at adult
synapses in many regions of the CNS
2.01 0.24
GGH Gamma-glutamyl hydrolase; Hydrolyzes the polyglutamate sidechains of
pteroylpolyglutamates. Progressively removes gamma-glutamyl residues from
pteroylpoly-gamma-glutamate to yield pteroyl-alpha- glutamate (folic acid) and free
glutamate. May play an important role in the bioavailability of dietary pteroylpolyglutamates
and in the metabolism of pteroylpolyglutamates and antifolates; Belongs to the peptidase
C26 family
2.10 0.27
CXCL8 Interleukin-8; IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells,
but not monocytes. It is also involved in neutrophil activation. It is released from several
cell types in response to an inflammatory stimulus. IL-8(6-77) has a 5-10-fold higher
activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation
and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to
IL-8(1-77), respectively; Chemokine ligands
2.13 0.13
IL15 Interleukin-15; Cytokine that stimulates the proliferation of T- lymphocytes. Stimulation by
IL-15 requires interaction of IL-15 with components of IL-2R, including IL-2R beta and
probably IL-2R gamma but not IL-2R alpha; Belongs to the IL-15/IL-21 family
2.20 0.59
DKK1 Dickkopf-related protein 1; Antagonizes canonical Wnt signaling by inhibiting LRP5/6
interaction with Wnt and by forming a ternary complex with the transmembrane protein
KREMEN that promotes internalization of LRP5/6
2.23 0.58
LEP Leptin; Key player in the regulation of energy balance and body weight control. Once
released into the circulation, has central and peripheral effects by binding LEPR, found in
many tissues, which results in the activation of several major signaling pathways.
2.30 0.13
RETN Resistin; Hormone that seems to suppress insulin ability to stimulate glucose uptake into
adipose cells (By similarity). Potentially links obesity to diabetes (By similarity). Promotes
chemotaxis in myeloid cells
2.30 0.10
IL32 Interleukin-32; Interleukin 32; Interleukins 2.40 0.31
CXCL9 C-X-C motif chemokine 9; Cytokine that affects the growth, movement, or activation state
of cells that participate in immune and inflammatory response. Chemotactic for activated
T-cells. Binds to CXCR3; Belongs to the intercrine alpha (chemokine CxC) family
2.49 0.59
IGFBP2 Insulin-like growth factor-binding protein 2; Inhibits IGF-mediated growth and
developmental rates. IGF-binding proteins prolong the half-life of the IGFs and have been
shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture.
They alter the interaction of IGFs with their cell surface receptors
2.50 0.008
PDGFB Platelet-derived growth factor subunit B; Growth factor that plays an essential role in the
regulation of embryonic development, cell proliferation, cell migration, survival and
chemotaxis. Potent mitogen for cells of mesenchymal origin. Required for normal
proliferation and recruitment of pericytes and vascular smooth muscle cells in the central
nervous system, skin, lung, heart and placenta. Required for normal blood vessel
development, and for normal development of kidney glomeruli
2.50 0.15
CSF2 Granulocyte-macrophage colony-stimulating factor; Cytokine that stimulates the growth
and differentiation of hematopoietic precursor cells from various lineages, including
granulocytes, macrophages, eosinophils and erythrocytes; Belongs to the GM-CSF family
2.52 0.55
CST3 Cystatin-C; As an inhibitor of cysteine proteinases, this protein is thought to serve an
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Node Annotation Fold change p-value
FGF2 Fibroblast growth factor 2; Plays an important role in the regulation of cell survival, cell
division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen
in vitro. Can induce angiogenesis; Belongs to the heparin-binding growth factors family
2.55 0.32
IL19 Interleukin-19; May play some important roles in inflammatory responses. Up-regulates
IL-6 and TNF-alpha and induces apoptosis (By similarity); Interleukins
2.60 0.36
TNFSF13B Tumor necrosis factor ligand superfamily member 13B; Cytokine that binds to
TNFRSF13B/TACI and TNFRSF17/BCMA. TNFSF13/APRIL binds to the same 2
receptors. Together, they form a 2 ligands −2 receptors pathway involved in the
stimulation of B- and T-cell function and the regulation of humoral immunity. A third B-cell
specific BAFF-receptor (BAFFR/BR3) promotes the survival of mature B-cells and the
B-cell response; CD molecules
2.71 0.31
C19orf10 Myeloid-derived growth factor; Bone marrow-derived monocyte and paracrine-acting
protein that promotes cardiac myocyte survival and adaptive angiogenesis for cardiac
protection and/or repair after myocardial infarction (MI). Stimulates endothelial cell
proliferation through a MAPK1/3-, STAT3-, and CCND1-mediated signaling pathway.
Inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent signaling pathway (By
similarity). Involved in endothelial cell proliferation and angiogenesis
2.90 0.38
CXCL12 Stromal cell-derived factor 1; Chemoattractant active on T-lymphocytes, monocytes, but
not neutrophils. Activates the C-X-C chemokine receptor CXCR4 to induce a rapid and
transient rise in the level of intracellular calcium ions and chemotaxis. Also binds to
atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts
as a scavenger receptor for SDF-1. SDF-1-beta(3-72) and SDF-1- alpha(3-67) show a
reduced chemotactic activity
2.90 0.27
IL1B Interleukin-1 beta; Potent proinflammatory cytokine. Initially discovered as the major
endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation,
T-cell activation and cytokine production, B-cell activation and antibody production, and
fibroblast proliferation and collagen production. Promotes Th17 differentiation of T-cells
2.90 0.51
PDGFA Platelet-derived growth factor subunit A; Growth factor that plays an essential role in the
regulation of embryonic development, cell proliferation, cell migration, survival and
chemotaxis. Potent mitogen for cells of mesenchymal origin. Required for normal lung
alveolar septum formation during embryogenesis, normal development of the
gastrointestinal tract, normal development of Leydig cells and spermatogenesis
3.00 0.09
MMP9 Matrix metalloproteinase-9; May play an essential role in local proteolysis of the
extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic
resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves type IV and type V collagen into
large C-terminal three quarter fragments and shorter N-terminal one quarter fragments.
Degrades fibronectin but not laminin or Pz-peptide; M10 matrix metallopeptidases
3.10 0.20
RLN1 Prorelaxin H1; Relaxin is an ovarian hormone that acts with estrogen to produce dilatation
of the birth canal in many mammals. May be involved in remodeling of connective tissues
during pregnancy, promoting growth of pubic ligaments and ripening of the cervix;
Belongs to the insulin family
3.10 0.61
TGFA Protransforming growth factor alpha; TGF alpha is a mitogenic polypeptide that is able to
bind to the EGF receptor/EGFR and to act synergistically with TGF beta to promote
anchorage-independent cell proliferation in soft agar
3.20 0.69
MOK MAPK/MAK/MRK overlapping kinase; Able to phosphorylate several exogenous
substrates and to undergo autophosphorylation. Negatively regulates cilium length in a
cAMP and mTORC1 signaling-dependent manner; Belongs to the protein kinase
superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily
3.30 0.73
CSF3 Granulocyte colony-stimulating factor; Granulocyte/macrophage colony-stimulating
factors are cytokines that act in hematopoiesis by controlling the production,
differentiation, and function of 2 related white cell populations of the blood, the
granulocytes and the monocytes-macrophages. This CSF induces granulocytes; Belongs
to the IL-6 superfamily
3.40 0.62
IL16 Pro-interleukin-16; Interleukin-16 stimulates a migratory response in CD4+ lymphocytes,
monocytes, and eosinophils. Primes CD4+ T-cells for IL-2 and IL-15 responsiveness. Also
induces T-lymphocyte expression of interleukin 2 receptor. Ligand for CD4; Interleukins
3.4 0.37
IL2 Interleukin-2; Produced by T-cells in response to antigenic or mitogenic stimulation, this
protein is required for T-cell proliferation and other activities crucial to regulation of the
immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells,
natural killer cells, and glioma cells; Interleukins
3.47 0.40
(Continued)
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FLT3LG Fms-related tyrosine kinase 3 ligand; Stimulates the proliferation of early hematopoietic
cells by activating FLT3. Synergizes well with a number of other colony stimulating factors
and interleukins; Endogenous ligands
3.50 0.60
IL11 Interleukin-11; Cytokine that stimulates the proliferation of hematopoietic stem cells and
megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in
increased platelet production. Also promotes the proliferation of hepatocytes in response
to liver damage. Binding to its receptor formed by IL6ST and either IL11RA1 or IL11RA2
activates a signaling cascade that promotes cell proliferation. Signaling leads to the
activation of intracellular protein kinases and the phosphorylation of STAT3; Belongs to the
IL-6 superfamily
3.51 0.14
CCL20 C-C motif chemokine 20; Acts as a ligand for C-C chemokine receptor CCR6. Signals
through binding and activation of CCR6 and induces a strong chemotactic response and
mobilization of intracellular calcium ions. The ligand-receptor pair CCL20-CCR6 is
responsible for the chemotaxis of dendritic cells (DC), effector/memory T-cells and B- cells
and plays an important role at skin and mucosal surfaces under homeostatic and
inflammatory conditions
3.60 0.51
ICAM1 Intercellular adhesion molecule 1; ICAM proteins are ligands for the leukocyte adhesion
protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans- endothelial migration,
ICAM1 engagement promotes the assembly of endothelial apical cups through
ARHGEF26/SGEF and RHOG activation; CD molecules
3.60 0.06
MIF Macrophage migration inhibitory factor; Pro-inflammatory cytokine. Involved in the innate
immune response to bacterial pathogens. The expression of MIF at sites of inflammation
suggests a role as mediator in regulating the function of macrophages in host defense.
Counteracts the anti- inflammatory activity of glucocorticoids. Has phenylpyruvate
tautomerase and dopachrome tautomerase activity (in vitro), but the physiological
substrate is not known. It is not clear whether the tautomerase activity has any
physiological relevance, and whether it is important for cytokine activity
3.60 0.10
CHI3L1 Chitinase-3-like protein 1; Carbohydrate-binding lectin with a preference for chitin. Has no
chitinase activity. May play a role in tissue remodeling and in the capacity of cells to
respond to and cope with changes in their environment. Plays a role in T-helper cell type 2
(Th2) inflammatory response and IL-13-induced inflammation, regulating allergen
sensitization, inflammatory cell apoptosis, dendritic cell accumulation and M2 macrophage
differentiation. Facilitates invasion of pathogenic enteric bacteria into colonic mucosa and
lymphoid organs
3.76 0.003
CCL17 C-C motif chemokine 17; Chemotactic factor for T-lymphocytes but not monocytes or
granulocytes. May play a role in T-cell development in thymus and in trafficking and
activation of mature T-cells. Binds to CCR4; Belongs to the intercrine beta (chemokine CC)
family
3.80 0.24
CCL3 C-C motif chemokine 3; Monokine with inflammatory and chemokinetic properties. Binds
to CCR1, CCR4, and CCR5. One of the major HIV-suppressive factors produced by
CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different
strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV); Belongs to the intercrine
beta (chemokine CC) family
3.80 0.63
CCL19 C-C motif chemokine 19; May play a role not only in inflammatory and immunological
responses but also in normal lymphocyte recirculation and homing. May play an important
role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary
lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows
potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes.
Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of
beta-arrestin (ARRB1/2) to ACKR4; Belongs to the intercrine beta (chemokine CC) family
3.90 0.23
IL34 Interleukin-34; Cytokine that promotes the proliferation, survival and differentiation of
monocytes and macrophages. Promotes the release of proinflammatory chemokines, and
thereby plays an important role in innate immunity and in inflammatory processes. Plays
an important role in the regulation of osteoclast proliferation and differentiation, and in the
regulation of bone resorption. Signaling via CSF1R and its downstream effectors stimulates
phosphorylation of MAPK1/ERK2 AND MAPK3/ERK1; Belongs to the IL-34 family
4.10 0.42
IL1RN Interleukin-1 receptor antagonist protein; Inhibits the activity of interleukin-1 by binding to
receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling.
Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater
affinity than decoy receptor IL1R2; however, the physiological relevance of the latter
association is unsure; Endogenous ligands
4.23 0.28
(Continued)
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IL23A Interleukin-23 subunit alpha; Associates with IL12B to form the IL-23 interleukin, a
heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may
constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a
heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak- Stat
signaling cascade, stimulates memory rather than naive T- cells and promotes production
of proinflammatory cytokines. IL-23 induces autoimmune inflammation
4.30 0.24
TFF3 Trefoil factor 3; Involved in the maintenance and repair of the intestinal mucosa. Promotes
the mobility of epithelial cells in healing processes (motogen)
4.36 0.21
CXCL10 C-X-C motif chemokine 10; Chemotactic for monocytes and T-lymphocytes. Binds to
CXCR3; Belongs to the intercrine alpha (chemokine CxC) family
4.40 0.36
TFRC Transferrin receptor protein 1; Cellular uptake of iron occurs via receptor-mediated
endocytosis of ligand-occupied transferrin receptor into specialized endosomes.
Endosomal acidification leads to iron release. The apotransferrin-receptor complex is then
recycled to the cell surface with a return to neutral pH and the concomitant loss of affinity
of apotransferrin for its receptor. Transferrin receptor is necessary for development of
erythrocytes and the nervous system (By similarity)
4.45 0.16
TNFRSF8 Tumor necrosis factor receptor superfamily member 8; Receptor for TNFSF8/CD30L. May
play a role in the regulation of cellular growth and transformation of activated
lymphoblasts. Regulates gene expression through activation of NF- kappa-B
4.47 0.44
CD14 Monocyte differentiation antigen CD14; Coreceptor for bacterial lipopolysaccharide. In
concert with LBP, binds to monomeric lipopolysaccharide and delivers it to the LY96/TLR4
complex, thereby mediating the innate immune response to bacterial lipopolysaccharide
(LPS). Acts via MyD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine
secretion and the inflammatory response
4.70 0.32
TNF Tumor necrosis factor; Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.
It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines.
It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1
secretion and is implicated in the induction of cachexia, Under certain conditions it can
stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg)
function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation
4.70 0.60
THBS1 Thrombospondin-1; Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix
interactions. Binds heparin. May play a role in dentinogenesis and/or maintenance of
dentin and dental pulp (By similarity). Ligand for CD36 mediating antiangiogenic properties.
Plays a role in ER stress response, via its interaction with the activating transcription factor
6 alpha (ATF6) which produces adaptive ER stress response factors (By similarity)
5.30 0.21
CCL2 C-C motif chemokine 2; Chemotactic factor that attracts monocytes and basophils but
not neutrophils or eosinophils. Augments monocyte anti-tumor activity. Has been
implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like
psoriasis, rheumatoid arthritis or atherosclerosis. May be involved in the recruitment of
monocytes into the arterial wall during the disease process of atherosclerosis; Belongs to
the intercrine beta (chemokine CC) family
5.70 0.23
FUT4 Alpha-(1,3)-fucosyltransferase 4; May catalyze alpha-1,3 glycosidic linkages involved in
the expression of Lewis X/SSEA-1 and VIM-2 antigens; CD molecules
6.30 0.59
IL10 Interleukin-10; Inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2,
IL-3, TNF, and GM-CSF produced by activated macrophages and by helper T-cells;
Belongs to the IL-10 family
6.69 0.33
TDGF1 Teratocarcinoma-derived growth factor 1; GPI-anchored cell membrane protein involved in
Nodal signaling. Cell-associated TDGF1 acts as a Nodal coreceptor in cis. Shedding of
TDGF1 by TMEM8A modulates Nodal signaling by allowing soluble TDGF1 to act as a
Nodal coreceptor on other cells. Could play a role in the determination of the epiblastic
cells that subsequently give rise to the mesoderm
7.04 0.69
BSG Basigin; Plays an important role in targeting the monocarboxylate transporters SLC16A1,
SLC16A3, SLC16A8, and SLC16A11 to the plasma membrane. Plays pivotal roles in
spermatogenesis, embryo implantation, neural network formation and tumor progression.
Stimulates adjacent fibroblasts to produce matrix metalloproteinases (MMPS). Seems to
be a receptor for oligomannosidic glycans. In vitro, promotes outgrowth of astrocytic
processes; Blood group antigens
7.15 0.01
(Continued)
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IL33 Interleukin-33; Cytokine that binds to and signals through the IL1RL1/ST2 receptor which
in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the
maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines.
Also involved in activation of mast cells, basophils, eosinophils and natural killer cells. Acts
as a chemoattractant for Th2 cells, and may function as an “alarmin,” that amplifies
immune responses during tissue injury; Interleukins
7.30 0.09
CXCL11 C-X-C motif chemokine 11; Chemotactic for interleukin-activated T-cells but not
unstimulated T-cells, neutrophils, or monocytes. Induces calcium release in activated
T-cells. Binds to CXCR3. May play an important role in CNS diseases which involve T-cell
recruitment. May play a role in skin immune responses; Belongs to the intercrine alpha
(chemokine CxC) family
8.90 0.12
ANGPT1 Angiopoietin-1; Binds and activates TEK/TIE2 receptor by inducing its dimerization and
tyrosine phosphorylation. Plays an important role in the regulation of angiogenesis,
endothelial cell survival, proliferation, migration, adhesion and cell spreading,
reorganization of the actin cytoskeleton, but also maintenance of vascular quiescence.
Required for normal angiogenesis and heart development during embryogenesis. After
birth, activates or inhibits angiogenesis, depending on the context
10.12 0.29
IGFBP3 Insulin-like growth factor-binding protein 3; IGF-binding proteins prolong the half-life of the
IGFs and have been shown to either inhibit or stimulate the growth promoting effects of
the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its
receptor TMEM219/IGFBP-3R
11.7 0.07
FGF7 Fibroblast growth factor 7; Plays an important role in the regulation of embryonic
development, cell proliferation and cell differentiation. Required for normal branching
morphogenesis. Growth factor active on keratinocytes. Possible major paracrine effector
of normal epithelial cell proliferation; Belongs to the heparin-binding growth factors family
12.1 0.54
PLAUR Urokinase plasminogen activator surface receptor; Acts as a receptor for urokinase
plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates
the proteolysis-independent signal transduction activation effects of U-PA. It is subject to
negative-feedback regulation by U-PA which cleaves it into an inactive form; CD molecules
12.9 0.09
CCL5 C-C motif chemokine 5; Chemoattractant for blood monocytes, memory T-helper cells
and eosinophils. Causes the release of histamine from basophils and activates
eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4,
and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells.
Recombinant RANTES protein induces a dose-dependent inhibition of different strains of
HIV-1, HIV-2, and simian immunodeficiency virus (SIV).
13.10 0.12
IL31 Interleukin-31; Activates STAT3 and possibly STAT1 and STAT5 through the IL31
heterodimeric receptor composed of IL31RA and OSMR. May function in skin immunity.
Enhances myeloid progenitor cell survival in vitro (By similarity). Induces RETNLA and
serum amyloid A protein expression in macrophages (By similarity); Interleukins
13.3 0.34
IL18 Interleukin-18; Augments natural killer cell activity in spleen cells and stimulates interferon
gamma production in T-helper type I cells; Belongs to the IL-1 family
13.6 0.10
EGF Pro-epidermal growth factor; EGF stimulates the growth of various epidermal and
epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic
hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via
engagement of EGFR and activation of the magnesium channel TRPM6. Can induce
neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro
14.4 0.28
C5 Complement C5; Activation of C5 by a C5 convertase initiates the spontaneous assembly
of the late complement components, C5-C9, into the membrane attack complex. C5b has
a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic
complex is assembled; C3 and PZP like, alpha-2-macroglobulin domain containing
16.20 0.13
VEGFA Vascular endothelial growth factor A; Growth factor active in angiogenesis, vasculogenesis
and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration,
inhibits apoptosis and induces permeabilization of blood vessels. Binds to the
FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin.
NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to
KDR but does not activate downstream signaling pathways, does not activate
angiogenesis and inhibits tumor growth
17.2 0.03
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FIGURE 5 | Higher frequency and activated state of T lymphocytes in diabetic mice. (A) Gating strategy for identification of CD4, CD8, CD19, and NK1.1 positive cells
in the BM, spleen, and peripheral blood of wt/db and db/db mice. Reported frequencies are illustrative of a representative case for each group. (B) Relative frequency
of CD4+ cells. (C) Relative frequency of CD8+ cells. (D) Relative frequency of B cells. (E) Relative frequency of NK cells. (F) Relative frequency of CD8+ cells
expressing the activation marker CD25. (G) Relative frequency of CD8+ cells expressing CD103. Values are mean ± SEM, with each point representing an individual
case.
naïve, CD44highCD62high population considered TCM, and the
CD44highCD62L− population considered TEM (Figure 6A).
Naïve cells were increased in BM of db/db mice (CD4+: 2.70-
fold, p = 0.02; CD8+: 1.44-fold p = 0.01), unaltered in the
spleen, and reduced in the peripheral blood (CD4+: 0.71-fold,
p = 0.26; CD8+: 0.64-fold, p = 0.0002), which resulted in the
abrogation of the peripheral to BM gradient seen in the control
mice (Figures 6B,C).
Type 2 diabetes on central memory cells did not show
differences between groups. Nonetheless, db/db mice manifested
a positive gradient between the BM and peripheral blood (CD4+:
2.98-fold, p = 0.0005; CD8+: 1.49-fold, p = 0.004) compared
with control mice, which did not show a difference between the
two districts (CD4+: p = 0.13; CD8+: p = 0.32) (Figures 6D,E).
CD4+ TEM cells were less abundant in BM of db/db mice (0.61-
fold, p< 0.0001) but unchanged in the other districts (Figure 6F).
There was no difference between groups concerning CD8+ TEM
cells (Figure 6G).
Altered Cytokine Profile in BM of db/db
Mice
Having shown the activation and redistribution of different
classes of immune cells in db/db mice, we next examined if this
was associated with an alteration of the cytokines content in
the BM. Of 40 factors tested, 32 were upregulated in the BM of
diabetic mice compared with the wt/db controls. Of these, 22
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FIGURE 6 | Increased central to peripheral memory cell gradient in diabetic mice. (A) Gating strategy for identification of CD44 and CD62L within CD4+ and CD8+
cells in the BM, spleen, and peripheral blood of wt/db and db/db mice. Reported frequencies are illustrative of a representative case for each group. (B) Relative
frequency of CD44−CD62Lhigh population within CD4+ cells. (C) Relative frequency of CD44−CD62Lhigh population within CD8+ cells. (D) Relative frequency of
CD44highCD62Lhigh population within CD4+ cells. (E) Relative frequency of CD44highCD62Lhigh population within CD8+ cells. (F) Relative frequency of
CD44highCD62L− population within CD4+ cells. (G) Relative frequency of CD44highCD62L− population within CD8+ cells. Values are mean ± SEM, with each point
representing an individual case. (H) Radar graph of modulated cytokine in BM of db/db mice. Measurements performed in a pool of four mice per group. (I) STRING
network of modulated factors.
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TABLE 3 | Cytokine and chemokines differentially modulated in BM of db/db mice.
Factor Characteristics
Ccl2 C-C motif chemokine 2; Chemotactic factor that attracts monocytes, but not neutrophils; Belongs to the intercrine beta (chemokine CC) family
(148 aa)
Ccl12 C-C motif chemokine 12; Chemotactic factor that attracts eosinophils, monocytes, and lymphocytes but not neutrophils. Potent monocyte active
chemokine that signals through CCR2. Involved in allergic inflammation and the host response to pathogens and may play a pivotal role during early
stages of allergic lung inflammation; Belongs to the intercrine beta (chemokine CC) family (104 aa)
Cccl11 Eotaxin; In response to the presence of allergens, this protein directly promotes the accumulation of eosinophils (a prominent feature of allergic
inflammatory reactions), but not lymphocytes, macrophages or neutrophils; Belongs to the intercrine beta (chemokine Cnterleukin-4; Participates in
at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It induces the expression of class II
MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also regulates the expression of the
low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates IL31R
Il4 Interleukin-4; Participates in at least several B-cell activation processes as well as of other cell types. It is a costimulator of DNA-synthesis. It
induces the expression of class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also
regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates IL31R
Ccl3 3C-C motif chemokine 3; Monokine with inflammatory, pyrogenic and chemokinetic properties. Has a potent chemotactic activity for eosinophils.
Binding to a high-affinity receptor activates calcium release in neutrophils; Belongs to the intercrine beta (chemokine CC) fa
Il16 Pro-interleukin-16; Interleukin-16 stimulates a migratory response in CD4+ lymphocytes, monocytes, and eosinophils. Primes CD4+ T-cells for IL-2
and IL-15 responsiveness. Also induces T-lymphocyte expression of interleukin 2 receptor. Ligand for CD4 (1322 aa)
Timp1 Metalloproteinase inhibitor 1; Metalloproteinase inhibitor that functions by forming one to one complexes with target metalloproteinases, such as
collagenases, and irreversibly inactivates them by binding to their catalytic zinc cofactor. Acts on MMP1, MMP2, MMP3, MMP7, MMP8, MMP9,
MMP10, MMP11, MMP12, MMP13, and MMP16. Does not act on MMP14 (By similarity). Also functions as a growth factor that regulates cell
differentiation, migration and cell death and activates cellular signaling cascades via CD63 and ITGB1. Plays a role in integrin signaling; Belongs to
the protease
Csf1 Macrophage colony-stimulating factor 1; Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of
hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of
proinflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the
regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. Required
for normal male
Csf2 Granulocyte-macrophage colony-stimulating factor; Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from
various lineages, including granulocytes, macrophages, eosinophils and erythrocytes (141 aa)
Ccl4 C-C motif chemokine 4; Monokine with inflammatory and chemokinetic properties (92 aa)
Cxcl13 C-X-C motif chemokine 13; Strongly chemotactic for B-lymphocytes, weakly for spleen monocytes and macrophages but no chemotactic activity
for granulocytes. Binds to BLR1/CXCR5. May play a role in directing the migration of B-lymphocytes to follicles in secondary
Tnf Tumor necrosis factor; Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce
cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated
in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation (235 aa)
Il17a Interleukin-17A; Ligand for IL17RA. The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and
IL17RC (By similarity). Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines (B)
Il1b Interleukin-1 beta; Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis,
neutrophil influx and activation, T-cell activation and cytokine production, B-cell activation and antibody production, and fibroblast proliferation and
collagen production; Belongs to the IL-1 family (269 aa)
Il2 Interleukin-2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities
crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer cells, n
Cxcl1 Growth-regulated alpha protein; Has chemotactic activity for neutrophils. Contributes to neutrophil activation during inflammation (By similarity).
Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. KC(5-72) shows a highly enhanced
hematopoietic activity; Belongs to the intercrine alpha (chemokine CxC) family (96 aa)
Gmcsf3 Granulocyte colony-stimulating factor; Granulocyte/macrophage colony-stimulating factors are cytokines that act in hematopoiesis by controlling
the production, differentiation, and function of 2 related white cell populations of the blood, the granulocytes and the monocytes-macrophages.
This CSF induces granulocytes; Belongs to the IL-6 superfamily (208 aa)
Trem Triggering receptor expressed on myeloid cells 1; Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of
pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses
that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock (By similarity) (230 aa)
Ccl5 C-C motif chemokine 5; Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of histamine from
basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4, and CCR5. May also be an agonist
of the G protein-coupled receptor GPR75. Together with GPR75, may play a role in neuron survival through activation of a downstream signaling
pathway involving the PI3, Akt and MAP kinases. By activating GPR75 may also play a role in insulin secretion by islet cells (91 aa)
Cxxl10 C-X-C motif chemokine 10; In addition to its role as a proinflammatory cytokine, may participate in T-cell effector function and perhaps T-cell
development; Belongs to the intercrine alpha (chemokine CxC) family (98 aa)
Cxcr3 C-X-C chemokine receptor type 3; Receptor for the C-X-C chemokine CXCL9, CXCL10, and CXCL11 and mediates the proliferation, survival and
angiogenic activity of mesangial cells through a heterotrimeric G-protein signaling pathway. Probably promotes cell chemotaxis
(Continued)
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TABLE 3 | Continued
Factor Characteristics
Cxcl2 C-X-C motif chemokine 2; Chemotactic for human polymorphonuclear leukocytes but does not induce che
Ccl1 C-C motif chemokine 1; Cytokine that is chemotactic for neutrophils; Belongs to the intercrine beta (chem)
Cxcl9 C-X-C motif chemokine 9; May be a cytokine that affects the growth, movement, or activation state of cells that participate in immune and
inflammatory response (126 aa)
Il23r Interleukin-23 receptor; Associates with IL12RB1 to form the interleukin-23 receptor. Binds IL23 and mediates T-cells, NK cells and possibly certain
macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity
and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be
important for tumorigenesis (By similarity) (659 aa)
Il7 Interleukin-7; Hematopoietic growth factor capable of stimulating the proliferation of lymphoid progenitors. It is important for proliferation during
certain stages of B-cell maturation (154 aa)
were uniquely expressed in db/db mice (Figures 6H,I, Table 3).
Results indicate the presence of an inflammatory environment
in BM, which may account for the recruitment and activation of
immune cells.
Rescue of Immune Profile of db/db Mice by
Abatacept
Altogether the above findings show a state of inflammation
in patients and mice with T2D. This involves activation of
adaptive immunity, as evidenced by the increase in CD25+ T
cells and corroborated by the upregulation of a multitude of
inflammation-associated mediators.
We next investigated the effect of the in vivo administration
of abatacept, a CTLA4-Ig fusion protein, on the immune profile
of 10-week-old db/db mice. Abatacept- and vehicle-treated
(control) mice were sacrificed 4 weeks later. Flow cytometry
analysis demonstrated that, compared with control, the abatacept
group had higher levels of CD4+ andCD8+ cells in the peripheral
blood (p < 0.01 for both comparisons) and, limited to CD8+
cells, in BM (p = 0.003), whereas no difference was detected
in the spleen (Figures 7A–C). The treatment did not affect
the abundance of CD19+ B lymphocytes (data not shown).
These changes in relative cell subsets abundance could be a side
effect of changes in chemokine expression after co-stimulation
blockade (43). Yet, most importantly, abatacept reduced the
proliferation (judged by marker Ki67) of CD4+ T cells in the
BM, spleen, and peripheral blood, as well of CD8+ T cells in
the periphery (Figures 7D,E). Corroborating these findings, the
levels of activation marker CD25 expressed by CD4+ T cells in
the BM and the spleen were suppressed by the anti-inflammatory
action of abatacept (p < 0.01 for both comparisons, Figure 7F)
though this was not seen in CD8+ T cells (Figure 7G). Moreover,
Abatacept reduced the frequency of CD4+ and CD8+ cells
expressing CD103 in all the areas examined (Figures 7H,I).
Examining the cytokine and chemokine production using a
Proteome Profiler Mouse Cytokine Array, we did not find any
major differences in the BM between abatacept and control-
treated animals (Figure 7J). However, in a manner compatible
with the systemic effect of abatacept (36), the drug led to
a relative reduction in the peripheral blood levels of key
classical (type 1) proinflammatory cytokines Il-1b and Il-12,
and chemokines Cxcl9, Ccl2/MCP1, Ccl4, and Ccl5, as well as
type 17 proinflammatory cytokine Il-17 and Il-23, indicating a
clear suppression of type 1 and type 17 proinflammatory signals,
as a result of the inhibition of T-cell activation (Figures 7K,L,
Table 4).
We further analyzed the abundance of APCs. Abatacept
decreased the number of DC in peripheral blood (3.3 ± 0.4 vs.
7.3± 1.2% in vehicle, p < 0.05) but did not alter the frequency of
macrophages (data not shown). Finally, we examined the effect of
abatacept on naïve and memory T cells (Figure 8A). Regarding
naïve cells, the abatacept-treated group showed a borderline
increase of the CD4+ fraction in BM (p = 0.05), whereas naïve
CD8+ cells were unaltered (Figures 8B,C). CD4+ TEM cells were
reduced by abatacept in BM and spleen (p < 0.0001 for both
comparisons), whereas CD8+ TEM cells were decreased only
in BM (p = 0.04). Figures 8D,E). TCM cells followed a more
heterogeneous behavior, the CD4+ fraction being reduced in the
spleen (p = 0.02) and the CD8+ fraction in the peripheral blood
(p= 0.04) (Figures 8F,G).
Metabolic and Functional Endpoints
Body weight and the weight of heart and spleen were similar
between groups given vehicle or abatacept (Figures 9A,B).
Likewise, there was no difference in the fasting levels of
insulin and glucose (data not shown), as well as in indexes of
insulin sensitivity HOMA-IR and QUICKI (Figures 9C,D). We
then analyzed the cardiac phenotype by echocardiography.
The study was conducted at an age when db/db mice
manifest echocardiographic evidence of left ventricular
(LV) dysfunction (44). abatacept induced an improvement
in echocardiographic indexes of systolic function compared
with controls (Figures 9E–G). Specifically, compared with the
control group, abatacept-treated mice showed higher cardiac
output (CO, p < 0.001) and stroke volume (SV, p < 0.01), which
could be reconducted to an increased preload, as suggested
by the increased LV end diastolic volume (EDV, p < 0.01)
(Figures 9H–M). However, abatacept did not reduce the LV
mass, thus discarding an anti-hypertrophic effect of the drug.
DISCUSSION
Recent evidence indicates that T cells play key roles in the
progression of T2D. In vitro studies on immune cells harvested
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FIGURE 7 | Effect of abatacept on immune cells of T2D mice. (A) Gating strategy for identification of CD4+ and CD8+ cells in the BM, spleen, and peripheral blood of
db/db mice given vehicle or abatacept. Reported frequencies are illustrative of a representative case for each group. (B) Relative frequency of CD4+ cells. (C) Relative
frequency of CD8+ cells. (D) Relative frequency of Ki67 expressing cells within CD4+ cells. (E) Relative frequency of Ki67 expressing cells within CD8+ cells. (F)
(Continued)
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FIGURE 7 | Relative frequency of CD25+ cells within CD4+ cells. (G) Relative frequency of CD25+ cells within CD8+ cells. (H) Relative frequency of CD103+ cells
within CD4+ cells. (I) Relative frequency of CD103+ cells within CD8+ cells. (J) Spider graph of cytokines in the BM of the abatacept (green line) and vehicle group
(orange line). (K) Spider graph of cytokines in the peripheral blood of the abatacept (green line) and vehicle group (orange line). Measurements were performed in a
pool of four mice per group. (L) Network analysis of regulated cytokines. Values are mean ± SEM, with each point representing an individual case.




3.98 Il27—Interleukin-27 subunit alpha; Associates with EBI3 to form the IL-27 interleukin, a heterodimeric cytokine which functions in
innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T- helper cell development, suppress T-cell
proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune
cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2)
and IL17 producing helper T-cells (TH17)
Ccl4 3.45 C-C motif chemokine 4; Monokine with inflammatory and chemokinetic properties
Il-13 2.75 Interleukin-13; Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis.
May be critical in regulating inflammatory and immune responses (By similarity). Positively regulates IL31RA expression in
macrophages
Il-23 2.65 Interleukin-23 subunit alpha; Associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in
innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to
a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak- Stat signaling cascade, stimulates
memory rather than naive T- cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune
inflammation and thus may be responsible for autoimmune inflammatory diseases
Il-2 2.30 Interleukin-2; Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation
and other activities crucial to regulation of the immune response. Can stimulate B-cells, monocytes, lymphokine- activated killer
cells, natural killer cells
Ccl5 2.21 C-C motif chemokine 5; Chemoattractant for blood monocytes, memory T-helper cells and eosinophils. Causes the release of
histamine from basophils and activates eosinophils. May activate several chemokine receptors including CCR1, CCR3, CCR4,
and CCR5. May also be an agonist of the G protein-coupled receptor GPR75. Together with GPR75, may play a role in neuron
survival through activation of a downstream signaling pathway involving the PI3, Akt and MAP kinases
Ccl17 2.13 Chemokine (C-C motif) ligand 17
CXCL12 2.11 Stromal cell-derived factor 1; Chemoattractant active on T-lymphocytes, monocytes, but not neutrophils. Activates the C-X-C
chemokine receptor CXCR4 to induce a rapid and transient rise in the level of intracellular calcium ions and chemotaxis. Also
binds to atypical chemokine receptor ACKR3, which activates the beta-arrestin pathway and acts as a scavenger receptor for
SDF-1. Acts as a positive regulator of monocyte migration and a negative regulator of monocyte adhesion via the LYN kinase.
Stimulates migration of monocytes and T- lymphocytes through its receptors, CXCR4
Cxcl9 2.07 C-X-C motif chemokine 9; May be a cytokine that affects the growth, movement, or activation state of cells that participate in
immune and inflammatory response
Il-4 2.0 Interleukin-4; Participates in at least several B-cell activation processes as well as of other cell types. It induces the expression of
class II MHC molecules on resting B-cells. It enhances both secretion and cell surface expression of IgE and IgG1. It also
regulates the expression of the low affinity Fc receptor for IgE (CD23) on both lymphocytes and monocytes. Positively regulates
IL31RA expression in macrophages
Il-6 0.02 Interleukin-6; Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an
essential role in the final differentiation of B-cells into Ig- secreting cells Involved in lymphocyte and monocyte differentiation. Acts
on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Required for the generation of T(H)17 cells.
Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of
fats and to improve insulin resistance
from the peripheral blood of subjects with T2D and ND
controls have shown that T2D is associated with overactivated
T cells and the induction of the inflammatory pathways (45–
47), thus positing the provoking hypothesis of T2D being an
autoimmune disease (48). The role of BM in the maintenance of
antigen-experienced adaptive immune cells is well-documented
as reviewed in Bonomo et al. (49). Nonetheless, little is known
about the immune profile of BM in T2D.
In the present study, we provide novel proof-of-concept
evidence for the activation of adaptive immunity in the BM of
patients and mice with T2D. The studied human diabetic cohort
had an increased frequency of BM T lymphocytes. Both CD4+
and CD8+ cells abundantly expressed CCR7, which, together
with the observed high levels of CCL19 (CCR7 receptor ligand),
suggests that the local BM environment was reshaped to favor
immune cell recruitment from the circulation. Moreover, we
demonstrated that the diabetic BM contains TCM cells that
have undergone recent activation. Most importantly, BM T cells
showed a clear upregulation of typical activationmarkers. Several
features of the adaptive immunity activation seen in patients were
confirmed in db/db mice. Finally, we proved that the treatment
with abatacept, which interferes with the co-stimulation signaling
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FIGURE 8 | Effect of abatacept on naïve and memory T cells of T2D mice. (A) Gating strategy for identification of CD44+ and CD62L+ within CD4+ and CD8+
fractions in the BM, spleen, and peripheral blood of db/db mice given vehicle or abatacept. Reported frequencies are illustrative of a representative case for each
group. (B) Relative frequency of naïve cells within CD4+ cells. (C) Relative frequency of naïve cells within CD8+ cells. (D) Relative frequency of TEM cells within CD4+
cells. (E) Relative frequency of TEM cells within CD8+ cells. (F) Relative frequency of TCM cells within CD4+ cells. (G) Relative frequency of TCM cells within CD8+
cells. Values are mean ± SEM, with each point representing an individual case.
mechanism, inhibited the activation of adaptive immunity, and
improved cardiac function in db/db mice.
Abundant fat depots of overweight/obese patients reportedly
contain autoreactive T cells that exert a cytotoxic effect on
adipocytes and fuel adipose inflammation (50, 51). Adipose tissue
is also contiguous with main lymphoid organs, such as lymph
nodes, thymus, and BM, participating in multiple intertwined
mechanisms (52). For instance, adipocytes surrounding the
thymus may influence T-cell differentiation in response to
metabolic challenges (53). Likewise, adipocytes that reside in
the BM are thought to play relevant roles in hematopoiesis,
lymphopoiesis, and memory B- and T-cell responses (21). BM
adiposity becomes more abundant with aging, in parallel with
a decline of immunity and hematopoietic functions (54). Fat
accumulation reported by us in the BM of patients and animal
models with T2D represents a significant difference (25, 27, 55).
In fact, the analysis of BM cells indicates a reactive adaptive
immunity. These new data complement our previous report
showing cytotoxic NK cells were significantly increased in the
BM of subjects with T2D (25). The cellular phenotype reported
in the present study was associated with alterations in the
levels of cytokines and chemokines that influence the lodging
and activation of naïve T cells and the maintenance of a
memory reservoir. It remains to be ascertained whether adaptive
immunity was induced by the previous exposure to foreign
antigens or could be reconducted to dysregulation of co-signaling
mechanisms that direct T-cell function and fate following
antigen presentation. Interestingly, we found that CD147 was
upregulated in the diabetic BM. This immunoglobulin acts as
the main upstream stimulator of matrix metalloproteinases and
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FIGURE 9 | Effect of abatacept on metabolic and cardiac endpoints. (A) Body weight, (B) Heart weight, (C,D) indices of insulin sensitivity, and (E–M) indices of
cardiac function. Values are mean ± SEM, with each point representing an individual case. **p < 0.01, and ***p < 0.001 vs. vehicle (V).
may have pathogenic roles in diabetic complications, through the
recruitment of immune cells. Intriguingly, CD147 is considered
a key route for severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) invasion of immune cells (38), which might
account for the susceptibility of diabetic patients to viral
infection (56).
The co-signaling factor CTLA4 exerts competitive inhibition
of T-cell activation (40). We tested the importance of this
signaling mechanism by treating T2D mice with abatacept, a
CTLA4-Ig fusion protein that exerts anti-inflammatory activity
and attenuates T-cell activation by inhibiting the CD80/86:CD28
co-stimulatory pathway. The murine CD28 has a 77% homology
with human CD28 (https://www.genecards.org/cgi-bin/
carddisp.pl?gene=CD28). Moreover, this immunomodulatory
drug showed cardioprotective effects in mice with pressure
overload-induced heart failure (36). In our study abatacept
inhibited T-cell activation and suppressed the production of
several key inflammatory cytokines and chemokines. Treg cells
are sensitive to co-stimulation perturbations, and it cannot be
excluded that the reduction in CD25 expressing T cells following
abatacept treatment is due to the effects on Treg. This possibility
warrants focused future investigation.
The clinical indication of abatacept is to treat active
rheumatoid arthritis, but seminal data are supporting its potential
in the treatment of Type 1 diabetes and cardiovascular disease.
In TrialNet study for people newly diagnosed, those who took
Abatacept showed 59% higher insulin production and prolonged
insulin production (57). Moreover, clinical studies in patients
with rheumatoid arthritis have shown that Abatacept treatment
reduced the risk of Type 1 or Type 2 diabetes, through an
anti-inflammatory mechanism preserving β-cell function (33–
35). A recent case report showed abatacept treatment led to
the resolution of glucocorticoid-refractory myocarditis caused by
rheumatoid arthritis or immune checkpoint inhibitor anti-cancer
treatment (58). Here, we showed that, although not capable of
improving insulin resistance, the anti-inflammatory action of
abatacept could benefit the cardiac function of db/db mice.
CONCLUSION
In the present study, we have shown the activation of
adaptive immunity in diabetic BM and the possibility to rescue
immune and cardiac abnormalities using the clinically available,
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immunomodulatory drug abatacept. The compound is not risk
free and the use in diabetes requires additional investigation
assessing safety and optimal risk-to-benefit context. Regarding
limitations, we could not perform analyses of peripheral blood
cells in the human study because the ethical license covered
the investigation of BM leftovers only. The focus of the
present study was on specific populations of lymphocytes, which
were found generally increased/activated. This change implies
a relative reduction in other BM cell populations expressing
the CD45 marker, an aspect that was not assessed in the
present study but documented previously by us and others
(25, 30, 59, 60). Considering the pilot nature of the work,
further investigation is necessary in large cohorts of patients
to determine whether the activation of adaptive immune cells
in BM is a general phenomenon or characterizes specific
subgroups of diabetic patients according to disease duration and
severity of complications. Moreover, an additional mechanistic
investigation is warranted on the causes responsible for the
concomitant T-cell activation and expansion of naïve T cells in
BM, the latter likely due to the increased homing from secondary
lymphoid organs. Finally, studies in models of diet-induced
diabetes could strengthen the novel evidence provided by data
from the genetically diabetic db/db mice.
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